# Efficacy and Safety of Atacicept in IgA Nephropathy

> **NCT02808429** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 16 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** Placebo
- **DRUG:** Atacicept 25 mg
- **DRUG:** Atacicept 75 mg

## Key facts

- **NCT ID:** NCT02808429
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-31
- **Primary completion:** 2020-02-07
- **Final completion:** 2020-02-07
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study was terminated early as per sponsor decision due to unexpectedly slow enrollment.
- **Last updated:** 2021-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808429, "Efficacy and Safety of Atacicept in IgA Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02808429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*